Education
About Us
Working with TipRanks
Follow Us
Bio-Rad Laboratories (BIO)
NYSE:BIO
BIO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$211.43 - $387.99
Previous CloseN/A
Volume33.84K
Average Volume (3M)296.10K
Market Cap
$7.80B
Enterprise Value$6.60B
Total Cash (Recent Filing)$1.37B
Total Debt (Recent Filing)$1.41B
Price to Earnings (P/E)24.6
Beta0.81
Next Earnings
Oct 23, 2025EPS Estimate
1.97Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.61
Shares Outstanding21,992,308
10 Day Avg. Volume199,901
30 Day Avg. Volume296,103
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue2.58
Enterprise Value/Gross Profit4.89
Enterprise Value/Ebitda9.62
Forecast
1Y Price Target
$333.00Price Target Upside15.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Financial ManagementThe CFO is targeting a significant increase in free cash flow by improving terms with suppliers and employing lean methods to reduce inventories.
Operational StrategyThe company is focusing on self-help measures and new management is executing strategies to improve margins and free cash flow.
Bears Say
Earnings OutlookForecasts for Bio-Rad's revenue and adjusted EBITDA have been reduced, reflecting a less optimistic outlook.
Regulatory ImpactBio-Rad Laboratories is expected to experience lower growth in their Life Sciences segment due to recent US policy changes and uncertainty around NIH funding.
Tariff ImpactTariffs are expected to be ~130bps headwind to operating profit margins, with US exports to China (in the Diagnostics segment) being the most significant piece.
Bio-Rad Laboratories News
BIO FAQ
What was Bio-Rad Laboratories’s price range in the past 12 months?
Bio-Rad Laboratories lowest stock price was $211.43 and its highest was $387.99 in the past 12 months.
What is Bio-Rad Laboratories’s market cap?
Bio-Rad Laboratories’s market cap is $7.80B.
When is Bio-Rad Laboratories’s upcoming earnings report date?
Bio-Rad Laboratories’s upcoming earnings report date is Oct 23, 2025 which is in 62 days.
How were Bio-Rad Laboratories’s earnings last quarter?
Bio-Rad Laboratories released its earnings results on Jul 31, 2025. The company reported $2.61 earnings per share for the quarter, beating the consensus estimate of $1.734 by $0.876.
Is Bio-Rad Laboratories overvalued?
According to Wall Street analysts Bio-Rad Laboratories’s price is currently Undervalued.
Does Bio-Rad Laboratories pay dividends?
Bio-Rad Laboratories does not currently pay dividends.
What is Bio-Rad Laboratories’s EPS estimate?
Bio-Rad Laboratories’s EPS estimate is 1.97.
How many shares outstanding does Bio-Rad Laboratories have?
Bio-Rad Laboratories has 21,992,308 shares outstanding.
What happened to Bio-Rad Laboratories’s price movement after its last earnings report?
Bio-Rad Laboratories reported an EPS of $2.61 in its last earnings report, beating expectations of $1.734. Following the earnings report the stock price went up 17.628%.
Which hedge fund is a major shareholder of Bio-Rad Laboratories?
Currently, no hedge funds are holding shares in BIO
Bio-Rad Laboratories Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$333.00 (15.56% Upside)
$333.00 (15.56% Upside)
Blogger Sentiment
Neutral
BIO Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-9.57%
12-Months-Change
Fundamentals
Return on Equity
4.59%
Trailing 12-Months
Asset Growth
5.43%
Trailing 12-Months
Company Description
Bio-Rad Laboratories
Bio-Rad Laboratories, Inc. is a global leader in the life sciences and clinical diagnostics sectors, providing innovative products and solutions that enhance research and healthcare. Founded in 1952, the company operates in two primary segments: Life Science and Clinical Diagnostics. Bio-Rad's core offerings include a wide range of reagents, instruments, and software used in laboratories for applications such as drug discovery, genetic research, and clinical diagnostics, enabling scientists and healthcare professionals to achieve accurate results efficiently.
BIO Company Deck
BIO Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlights Bio-Rad's strong financial performance, successful acquisitions and product launches, and improved cash flow, but also notes challenges in diagnostics sales, gross margin, and market softness in biotech and academic sectors.View all BIO earnings summariesBIO Net sales Breakdown
59.92% Clinical Diagnostics
40.06% Life Science
0.02% Other
BIO Stock 12 Month Forecast
Average Price Target
$333.00
▲(15.56% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---